Key result
Not all TIA patients require hospital admission if evaluated and treated promptly, and short-term dual antiplatelet therapy may be beneficial for select patients.
Why the study?
Does hospital admission or short-term dual antiplatelet therapy reduce recurrent stroke in patients with TIA?
Does hospital admission or short-term dual antiplatelet therapy reduce recurrent stroke in patients with TIA?
Prompt outpatient evaluation of TIA is often safe and effective, and short-term dual antiplatelet therapy may offer benefits for select patients, though optimal patient selection requires further study.
Answers are grounded in this paper and cite their sources.
Supports selective outpatient TIA evaluation; leaves open optimal DAPT selection and risk stratification for stroke prevention.
Transient ischemic attack (TIA) has gained increasing attention over the last 2 decades with the realization that the condition is common, portends potentially serious consequences, and, when identified early, can be evaluated and treated to modify future risk. In this review, we examine the issues of whether all TIA patients need admission and whether such patients should receive short-term dual antiplatelet therapy. Not all patients require admission if evaluation and treatment are done promptly. There may be a role for dual antiplatelet therapy, but the results of further clinical trials will help provide better clarity on which patients are the best candidates for this treatment.
No takes yet. Share an insight, caveat, or question.
Mijalski et al. (2015) conducted a review in Transient ischemic attack (TIA). Hospital admission and dual antiplatelet therapy vs. Outpatient management and monotherapy was evaluated. Not all TIA patients require hospital admission if evaluated and treated promptly, and short-term dual antiplatelet therapy may be beneficial for select patients.
Synapse has enriched 10 related papers. Consider them for comparative context: